J
Jun Liu
Researcher at China Pharmaceutical University
Publications - 97
Citations - 2736
Jun Liu is an academic researcher from China Pharmaceutical University. The author has contributed to research in topics: Glycogen phosphorylase & Oleanolic acid. The author has an hindex of 25, co-authored 90 publications receiving 2266 citations. Previous affiliations of Jun Liu include University of Florida & University of New Mexico.
Papers
More filters
Journal ArticleDOI
Naturally Occurring Pentacyclic Triterpenes as Inhibitors of Glycogen Phosphorylase: Synthesis, Structure−Activity Relationships, and X-ray Crystallographic Studies†
Xiaoan Wen,Hongbin Sun,Jun Liu,Keguang Cheng,Pu Zhang,Liying Zhang,Jia Hao,Luyong Zhang,Peizhou Ni,Spyros E. Zographos,Demetres D. Leonidas,K.-M. Alexacou,Thanasis Gimisis,Joseph Hayes,Nikos G. Oikonomakos +14 more
TL;DR: Pentacyclic triterpenes represent a promising class of multiple-target antidiabetic agents that exert hypoglycemic effects, at least in part, through GP inhibition.
Journal ArticleDOI
Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity
Li Wang,Isabelle Le Mercier,Juan Putra,Wenna Chen,Jun Liu,Austin D. Schenk,Elizabeth C. Nowak,Arief A. Suriawinata,Jiannan Li,Randolph J. Noelle +9 more
TL;DR: It is suggested that VISTA is a negative checkpoint regulator whose loss of function lowers the threshold for T-cell activation, allowing for an enhanced proinflammatory phenotype and an increase in the frequency and intensity of autoimmunity under susceptible conditions.
Journal ArticleDOI
Rapamycin induces heme oxygenase-1 in human pulmonary vascular cells: implications in the antiproliferative response to rapamycin.
TL;DR: In this paper, the authors evaluated whether there is an interaction between rapamycin and HO-1 and found that Rapamycin is an immunosuppressive agent with antiproliferative properties against not only lymphocytes but also vascular endothelial and smooth muscle cells.
Journal ArticleDOI
Pentacyclic triterpenes. Part 1: the first examples of naturally occurring pentacyclic triterpenes as a new class of inhibitors of glycogen phosphorylases.
TL;DR: It is proposed that naturally occurring pentacyclic triterpenes 1 and 2 might reduce blood glucose, at least in part, through inhibiting hepatic glycogen degradation.
Journal ArticleDOI
Luteolin inhibits ROS-activated MAPK pathway in myocardial ischemia/reperfusion injury.
TL;DR: Results reveal a ROS-MAPK mediated mechanism and mitochondrial pathway through which luteolin can protect myocardial ischemia/reperfusion injury.